ARCT 810
Alternative Names: ARCT-810; LUNAR-OTCLatest Information Update: 09 Jan 2025
At a glance
- Originator Arcturus Therapeutics
- Class RNA
- Mechanism of Action Ornithine carbamoyltransferase expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Ornithine carbamoyltransferase deficiency disease
Most Recent Events
- 06 Jan 2025 EMA approves the pediatric investigation plan for Ornithine transcarbamylase deficiency, prior to January 2025
- 01 Nov 2024 Arcturus Therapeutics terminates a phase II trial in Ornithine carbamoyltransferase deficiency disease (In adolescents, In children, In adults) in Belgium, Sweden, Spain, France, Italy, United Kingdom (IV), due to slow enrollment (NCT05526066)
- 10 Jun 2024 Phase-II clinical trials in Ornithine carbamoyltransferase deficiency disease (In adolescents, In children, In adults, In the elderly) in USA (IV) (NCT06488313)